

PRELIMINARY PROGRAM



International Parkinson and
Movement Disorder Society

MDS *Virtual* *Congress* 2020

SEPTEMBER 12–SEPTEMBER 16
www.mdscongress.org



TABLE OF CONTENTS

Welcome.....	2	Daily Schedule	7
About MDS.....	3	Schedule-at-a-Glance	7
Purpose, Mission and Goals.....	3	Virtual Congress Session Definitions.....	8
MDS Officers (2019-2021)	3	Friday, September 11, 2020	9
MDS International Executive Committee	4	Saturday, September 12, 2020	9
MDS Virtual Congress 2020 Task Force	4	Sunday, September 13, 2020	10
Congress Scientific Program Committee	4	Monday, September 14, 2020	16
Congress Local Organizing Committee	4	Tuesday, September 15, 2020	20
Past-Presidents	4	Wednesday, September 16, 2020.....	24
International Medical Society for Motor Disturbances Past-Presidents.....	4	Non-CME Educational Activities	26
MDS International Secretariat	4	Faculty Listing.....	27
Virtual Congress Information	5	Acknowledgements	30
Abstract Poster Information	5	Membership Information	32
Exhibition.....	5		
Official Language	5		
Registration	5		
Virtual Congress Events	6		
CME Information	6		

WELCOME

Dear Colleagues,

We are excited to share this MDS Virtual Congress with you. In this first ever virtual congress on movement disorders, you can expect over 30 hours of educational content through our virtual platform, including plenary sessions, teaching courses and access to the accepted abstracts.

The Society made the difficult decision to replace the in-person meeting in Philadelphia with a virtual meeting, and by doing so, is rising to the occasion after the COVID-19 crisis in order to fulfill its mission. This meeting will be open to healthcare professionals across the globe and will allow delegates an opportunity to access the full International Congress Scientific Program content through a virtual platform without concern for health, welfare or travel.

The MDS Virtual Congress 2020 scientific sessions, sponsored symposia, virtual exhibits, and poster sessions will be available on demand for free until October 1, 2020 for those participants who have registered by September 16, 2020. After October 1, 2020 the Virtual Congress will continue to be available on demand for MDS Members for a limited time.

Although we will not meet together in Philadelphia this September, I am proud to see the MDS community come together virtually to achieve our mission.



Claudia Trenkwalder
President, International Parkinson and Movement Disorder Society, 2019-2021



ABOUT MDS

The International Parkinson and Movement Disorder Society (MDS) is a professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson's disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control.

PURPOSE, MISSION AND GOALS

Purpose:

The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

Mission and Goals:

To disseminate knowledge about Movement Disorders by:

- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
- Sponsoring International Congresses and Symposia on Movement Disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:

- Using the Society's influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance to:

- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty

MDS OFFICERS (2019-2021)



President
Claudia Trenkwalder
Germany



President-Elect
Francisco Cardoso
Brazil



Secretary
Bastiaan Bloem
Netherlands



Secretary-Elect
Charles Adler
USA



Treasurer
Louis CS Tan
Singapore



Treasurer-Elect
Irene Litvan
USA



Past-President
Christopher Goetz
USA

ABOUT MDS

MDS INTERNATIONAL EXECUTIVE COMMITTEE

Shengdi Chen
Mark Edwards
Cristian Falup-Pecurariu
Joaquim Ferreira
Marina de Koning-Tijssen
Alice Nieuwboer
D. James Surmeier
Pille Taba
Mayela Rodriguez-Violante
Ruey-Meei Wu

MDS VIRTUAL CONGRESS 2020 TASK FORCE

Chairs: Vincenzo Bonifati, *Netherlands*
Chairs: Oscar Gershanik, *Argentina*
Chairs: Claudia Trenkwalder, *Germany*
Francisco Cardoso, *Brazil*
Margherita Fabbri, *Italy*
Hyder Jinnah, *USA*
Andrew Siderowf, *USA*
Matthew Stern, *USA*
Louis Tan, *Singapore*

CONGRESS SCIENTIFIC PROGRAM COMMITTEE

Chair: Vincenzo Bonifati, *Netherlands*
Co-Chair: Andrew Siderowf, *USA*
Orlando Barsottini, *Brazil*
Roongroj Bhidayasiri, *Thailand*
Per Borghammer, *Denmark*
Francisco Cardoso, *Brazil*
Pietro Cortelli, *Italy*
Alberto Espay, *USA*
Jennifer Friedman, *USA*
Jennifer Goldman, *USA*
Etienne Hirsch, *France*
Beomseok Jeon, *South Korea*
Andrea Kühn, *Germany*
Shen-Yang Lim, *Malaysia*
Karen Marder, *USA*
Wassilios Meissner, *France*
Tiago Outeiro, *Germany*
Maria Stamelou, *Greece*
Carolyn Sue, *Australia*
Ryosuke Takahashi, *Japan*
Claudia Trenkwalder, *Germany*
Ad-Hoc Member: Terry Ellis, *USA*
Ad-Hoc Member: Oscar Gershanik, *Argentina*
Ad-Hoc Member: Hyder Jinnah, *USA*
Ad-Hoc Member: Ron Postuma, *Canada*
Ad-Hoc Member: Veronica Santini, *USA*

CONGRESS LOCAL ORGANIZING COMMITTEE

Chair: Matthew Stern, *USA*
Co-Chair: Andrew Siderowf, *USA*
Nabila Dahodwala, *USA*
Andres Deik, *USA*
Jill Farmer, *USA*
Pedro Gonzalez-Alegre, *USA*
Dan Kremens, *USA*
Tsao-Wei Liang, *USA*
Meredith Spindler, *USA*
Dan Weintraub, *USA*
Allison Willis, *USA*

PAST-PRESIDENTS

2017-2019 Christopher Goetz, *USA*
2015-2017 Oscar Gershanik, *Argentina*
2013-2015 Matthew Stern, *USA*
2011-2013 Günther Deuschl, *Germany*
2009-2011 Philip Thompson, *Australia*
2007-2009 Anthony Lang, *Canada*
2005-2006 Andrew Lees, *United Kingdom*
2003-2004 C. Warren Olanow, *USA*
2001-2002 Werner Poewe, *Austria*
1999-2000 Mark Hallett, *USA*
1997-1998 Eduardo Tolosa, *Spain*
1995-1996 Joseph Jankovic, *USA*
1991-1994 C. David Marsden, *United Kingdom*
1988-1991 Stanley Fahn, *USA*

INTERNATIONAL MEDICAL SOCIETY FOR MOTOR DISTURBANCES PAST-PRESIDENTS

1993-1994 C. Warren Olanow, *USA*
1991-1992 Bastian Conrad, *Germany*
1989-1990 Mark Hallett, *USA*
1987-1988 Mario Manfredi, *Italy*
1985-1986 C. David Marsden, *United Kingdom*

MDS INTERNATIONAL SECRETARIAT

International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
Email: info@movementdisorders.org
Website: www.movementdisorders.org



VIRTUAL CONGRESS INFORMATION

ABSTRACT POSTER INFORMATION

Beginning on September 11, 2020, Virtual Congress participants can view e-posters in the Virtual Poster Hall. Additionally, all abstracts will be published in the Movement Disorders journal e-supplement.

The MDS Virtual Congress 2020 will also feature sixteen virtual Guided Poster Tours which will be open to all participants.

EXHIBITION

Participants will have the opportunity to visit the Virtual Exhibit Hall beginning on September 12, 2020.

OFFICIAL LANGUAGE

The official language of the 2020 Virtual Congress is English.

REGISTRATION

Registration will open on July 27, 2020 and will be offered to participants at no charge. The MDS Virtual Congress 2020 scientific sessions, sponsored symposia, virtual exhibits, and the virtual poster hall will be available on-demand for free until October 1, 2020 for those participants who have registered by September 16, 2020. After October 1, 2020 the Virtual Congress will continue to be available on demand for MDS Members for a limited time.

VIRTUAL CONGRESS EVENTS

WELCOME CEREMONY

Friday, September 11, 2020

Time: 15:00 – 16:00 GMT

All participants are encouraged to attend the Virtual Congress Welcome Ceremony. MDS President Claudia Trenkwalder and other MDS leaders will introduce this inaugural event and give a preview of what to expect throughout the week.

MDS VIRTUAL VIDEO CHALLENGE

Sunday, September 13, 2020

Time: 19:30 – 22:30 GMT

Monday, September 14, 2020

Time: 2:00 – 5:00 GMT

Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host world-renowned Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by Movement Disorder Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for participants to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

CME INFORMATION

TARGET AUDIENCE

Clinicians, researchers, post-doctoral fellows, medical residents, medical students, allied health professionals with an interest in current clinical trends and approaches for diagnosis and treatment of movement disorders.

OBJECTIVES

1. Evaluate the pharmacological and non-pharmacological management options available for Parkinson's disease and other movement disorders
2. Discuss the diagnostic approaches and tools available for Parkinson's disease and other movement disorders
3. Describe the pathogenesis and neurobiology of Parkinson's disease and other movement disorders

SATISFACTORY COMPLETION

Your chosen sessions must be attended in their entirety. Partial credit of individual sessions is not available. If you are seeking continuing education credit for a specialty, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Parkinson and Movement Disorder Society is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The International Parkinson and Movement Disorder Society designates this live activity for a maximum of 28.5 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTENT VALIDITY STATEMENT


All recommendations involving clinical medicine in MDS activities are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the case of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendations conforms to the generally accepted standards of experimental design, data collection and analysis. Activities that promote recommendations, treatment or manners of practicing medicine not within the definition of CME or are knowing to have risks or dangers that outweigh the benefits or are knowing to be ineffective in the treatment of patients do not constitute valid CME.

SCHEDULE-AT-A-GLANCE

	FRIDAY September 11	SATURDAY September 12	SUNDAY September 13	MONDAY September 14	TUESDAY September 15	WEDNESDAY September 16
2:00			Therapeutic Plenary Session Encore Presentation 2:00 - 4:00 GMT	Virtual MDS Video Challenge Encore Presentation 2:00 - 5:00 GMT		KEY CME Accredited Sessions Non-CME Educational Activities Sponsored Symposia (non-CME) MDS Activities and Events Breaks
2:30						
3:00						
3:30						
4:00			Break 4:00 - 4:30 GMT			
4:30			Therapeutic Plenary Session Encore Presentation 4:30 - 6:30 GMT			
5:00						
5:30						
6:00		MDS-AOS Regional Assembly 6:00 - 6:30 GMT				
6:30			Break 6:30 - 7:00 GMT			
7:00			Therapeutic Plenary Session Encore Presentation 7:00 - 9:00 GMT			
7:30						
8:00						
8:30						
9:00			Break 9:00 - 9:30 GMT			
9:30			Therapeutic Plenary Session Encore Presentation 9:30 - 11:30 GMT			
10:00						
10:30						
11:00						
11:30			Break 11:30 - 12:00 GMT			
12:00		Therapeutic Plenary Session 12:00 - 14:00 GMT	Plenary Session 12:00 - 14:00 GMT	Plenary Session 12:00 - 14:00 GMT	Plenary Session 12:00 - 14:00 GMT	Plenary Session 12:00 - 14:00 GMT
12:30						
13:00						
13:30						
14:00		Break 14:00 - 14:30 GMT	MDS-Business Meeting 14:00 - 14:30 GMT	Break 14:00 - 14:30 GMT	Break 14:00 - 14:30 GMT	Break 14:00 - 14:30 GMT
14:30			MDS-ES Regional Assembly 14:00 - 14:30 GMT			
15:00	Welcome Ceremony 15:00 - 16:00 GMT	Therapeutic Plenary Session 14:30 - 16:30 GMT	Parallel Sessions / Teaching Courses 14:30 - 16:30 GMT	Parallel Sessions / Teaching Courses 14:30 - 16:30 GMT	Parallel Sessions / Teaching Courses 14:30 - 16:30 GMT	Plenary Sessions 14:30 - 16:30 GMT
15:30				Science of Industry (non- CME) Session 14:30 - 16:30 GMT	Science of Industry (non- CME) Session 14:30 - 16:30 GMT	
16:00						
16:30		Sponsored Symposia 16:30 - 17:30 GMT	Sponsored Symposia 16:30 - 17:30 GMT	Sponsored Symposia 16:30 - 17:30 GMT	Sponsored Symposia 16:30 - 17:30 GMT	
17:00						
17:30		Break 17:30 - 18:00 GMT	MDS-Africa Regional Assembly 17:30 - 18:00 GMT	Break 17:30 - 18:00 GMT	Break 17:30 - 18:00 GMT	
18:00		Therapeutic Plenary Session 18:00 - 20:00 GMT	Skills Workshops / Special Topics in Movement Disorders / Video Sessions 18:00 - 19:30 GMT	Skills Workshops / Special Topics in Movement Disorders / Video Sessions 18:00 - 19:30 GMT	Skills Workshops / Special Topics in Movement Disorders / Video Sessions 18:00 - 19:30 GMT	
18:30						
19:00						
19:30						
20:00		Break 20:00 - 20:30 GMT				
20:30		Therapeutic Plenary Session 20:30 - 22:30 GMT	Virtual MDS Video Challenge 19:30 - 22:30 GMT			
21:00						
21:30						
22:00						MDS-PAS Regional Assembly 22:30 - 23:00 GMT

VIRTUAL CONGRESS SESSION DEFINITIONS

CME Accredited Sessions

2020 Virtual Congress Themed Sessions: At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year's theme, *The Combined Multidisciplinary Approach to Movement Disorders*, will be showcased with international experts serving as faculty. Meeting participants can elect to attend any or all of these sessions. Themed sessions are designated in the program with .

NEW in 2020: "Neuroscience Bridges" Plenary Session: In this session world-renowned neuroscientists provide overviews of their clinical or basic research, on topics of broad interest and relevance for the advancement of knowledge on the nervous system in physiology and pathology.

Controversies: This Plenary Session is designed to involve all Virtual Congress participants. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected "hot" topics will be open for debate among the panelists.

"Highlights for 2020: Looking Towards 2021" Plenary Session: In this session MDS experts present compilations of the hottest clinical and basic research articles published in the past year in the whole field of the Movement Disorders, and expected to impact heavily on the future research.

Parallel Sessions: These concurrent sessions provide an in-depth summary of new clinical and basic research findings, state-of-the-art treatment options, and future strategies on a variety of focused topics within the field of Movement Disorders.

Plenary Sessions: These sessions provide an overview of the latest clinical and basic science research findings and state-of-the-art information relating to topics of broad interest within the field of Movement Disorders.

Skills Workshops: These concurrent sessions provide practical illustrations of clinical or scientific techniques relevant to the field of Movement Disorders through video examples and equipment demonstrations.

Special Topics in Movement Disorders: These interactive sessions address "hot" topics in science or medicine using a variety of different formats that may include lectures, video presentations, and audience interaction.

Teaching Courses: These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides.

Therapeutic Plenary Sessions: These sessions provide an overview of the latest, state-of-the-art treatment options in the diagnosis and management of Parkinson's disease and other movement disorders.

Video Sessions: These concurrent sessions focus on video demonstrations to provide an overview of clinical movement disorders.

Non-CME Accredited Educational Activities

Science of Industry Sessions: These interactive sessions will provide attendees with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

Sponsored Symposia

Sponsored Symposia: These company-based informational sessions provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

Video Challenge

Video Challenge: The goal of this session is for attendees to learn from a series of unusual patients and observe how senior experts approach a challenging case. A world-renowned panel of Movement Disorders experts guide attendees through unique Movement Disorder cases as they are presented by representatives from Movement Disorder centers around the world.

VIRTUAL CONGRESS FACULTY ROLES

Chair: Facilitates the learnings of the session; ensures that learning objectives are met during the presentation(s), and engages the learners as needed.

CSPC Liaison: Develops the session from the onset; provides guidance to ensure that the learning objectives are met; interacts with Speakers / Presenters to ensure presentations are well integrated and overlap is minimized.

Speaker / Presenter: Creates and delivers the presentation materials, and participates in the dialogue of the session.

2020 VIRTUAL CONGRESS THEME

At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year's theme is *The Combined Multidisciplinary Approach to Movement Disorders*. International experts will serve as faculty, and the meeting participants can elect to attend any or all of these sessions.



Themed sessions



FRIDAY, SEPTEMBER 11, 2020

Welcome Ceremony

15:00 - 16:00 GMT

All participants are encouraged to attend the Virtual Congress Welcome Ceremony.

SATURDAY, SEPTEMBER 12, 2020

MDS-AOS Regional Assembly

6:00 - 6:30 GMT

All participants from Asia and Oceania are encouraged to attend.

101: Therapeutic Plenary Session

Updates on Medical Management Strategies for Parkinson's Disease: Motor Aspects

12:00 - 14:00 GMT

Chairs:

Matthew B. Stern, *USA*

Pille Taba, *Estonia*

Early Pharmacologic Management

Oscar Gershanik, *Argentina*

Rehabilitation Strategies

Alice Nieuwboer, *Belgium*

Medical Management Strategies for Advancing Disease Patients

Regina Katzenschlager, *Austria*

CSPC Liaison: Shen Yang Lim, *Malaysia*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss current management of early-stage Parkinson's disease
2. Review the role of rehabilitation, including physical, occupational and speech therapies, and exercise in Parkinson's disease
3. Describe current medical management strategies for advancing Parkinson's disease (motor complications and other late-stage features)

MDS Business Meeting

14:00 - 14:30 GMT

All participants are encouraged to attend.

102: Therapeutic Plenary Session

Parkinson's Disease: Non-Motor Aspects

14:30 - 16:30 GMT

Chairs:

Angelo Antonini, *Italy*

Daniel Weintraub, *USA*

Neuropsychiatric Features

Anette Schrag, *United Kingdom*

Dysautonomia

Horacio Kaufmann, *USA*

Sleep and Fatigue

Ron Postuma, *Canada*

CSPC Liaison: Jennifer Goldman, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the neuropsychiatric aspects of Parkinson's disease and their management
2. Discuss the recognition and management of dysautonomia in Parkinson's disease
3. Summarize the symptoms and management of sleep and fatigue in Parkinson's disease

103: Therapeutic Plenary Session

Therapeutic Approaches to Chorea, Dystonia, and Myoclonus

18:00 - 20:00 GMT

Chairs:

Francisco Cardoso, *Brazil*

Eduardo Tolosa, *Spain*

Chorea

Ruth Walker, *USA*

Dystonia

Rachel Saunders-Pullman, *USA*

Myoclonus

Yoshikazu Ugawa, *Japan*

CSPC Liaison: Francisco Cardoso, *Brazil*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. List the therapeutics options to manage patients with different types of chorea
2. Discuss the therapeutic management of dystonia
3. Summarize the therapeutic options for myoclonus

SATURDAY, SEPTEMBER 12, 2020

104: Therapeutic Plenary Session

Neurosurgical Management of Movement Disorders

20:30 – 22:30 GMT

Chairs: Günther Deuschl, *Germany*
Andrea Kühn, *Germany*

Technical Advances for DBS Treatment
Jens Volkmann, *Germany*

Long-term Effects of DBS on Motor and Non-motor
Symptoms in Parkinson's Disease
Patricia Limousin, *United Kingdom*

Alternative Strategies: Focused Ultrasound and Other
Lesioning Techniques in Movement Disorders
José Obeso, *Spain*

CSPC Liaison: Andrea Kühn, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss and apply new DBS techniques such as segmented leads for current steering, imaging guided programming, VTA models
2. Discuss indications of DBS and explain motor and non-motor benefits and risks
3. Discuss the pros and cons of different surgical approaches in movement disorders

SUNDAY, SEPTEMBER 13, 2020

101: Therapeutic Plenary Session (Encore Presentation)

Updates on Medical Management Strategies for Parkinson's Disease: Motor Aspects

2:00 – 4:00 GMT

Chairs: Roongroj Bhidayasiri, *Thailand*
Shengdi Chen, *Peoples Republic of China*

Early Pharmacologic Management
Oscar Gershanik, *Argentina*

Rehabilitation Strategies
Alice Nieuwboer, *Belgium*

Medical Management Strategies for Advancing Disease
Patients
Regina Katsenschlager, *Austria*

CSPC Liaison: Shen Yang Lim, *Malaysia*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss current management of early-stage Parkinson's disease
2. Review the role of rehabilitation, including physical, occupational and speech therapies, and exercise in Parkinson's disease
3. Describe current medical management strategies for advancing Parkinson's disease (motor complications and other late-stage features)

102: Therapeutic Plenary Session (Encore Presentation)

Parkinson's Disease: Non-Motor Aspects

4:30 – 6:30 GMT

Chairs: Huifang Shang, *Peoples Republic of China*
Louis Tan, *Singapore*

Neuropsychiatric Features
Anette Schrag, *United Kingdom*

Dysautonomia
Horacio Kaufmann, *USA*

Sleep and Fatigue
Ron Postuma, *Canada*

CSPC Liaison: Jennifer Goldman, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the neuropsychiatric aspects of Parkinson's disease and their management
2. Discuss the recognition and management of dysautonomia in Parkinson's disease
3. Summarize the symptoms and management of sleep and fatigue in Parkinson's disease

SUNDAY, SEPTEMBER 13, 2020

103: Therapeutic Plenary Session (Encore Presentation)

Therapeutic Approaches to Chorea, Dystonia, and Myoclonus

7:00 – 9:00 GMT

Chairs: Ruey-Meei Wu, *Taiwan*

Chorea

Ruth Walker, *USA*

Dystonia

Rachel Saunders-Pullman, *USA*

Myoclonus

Yoshikazu Ugawa, *Japan*

CSPC Liaison: Francisco Cardoso, *Brazil*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. List the therapeutic options to manage patients with different types of chorea
2. Discuss the therapeutics management of dystonia
3. Summarize the therapeutic options for myoclonus

104: Therapeutic Plenary Session (Encore Presentation)

Neurosurgical Management of Movement Disorders

9:30 – 11:30 GMT

Chairs: Ritsuko Hanajima, *Japan*

Beomseok Jeon, *South Korea*

Technical Advances for DBS Treatment

Jens Volkmann, *Germany*

Long-term Effects of DBS on Motor and Non-motor

Symptoms in Parkinson's Disease

Patricia Limousin, *United Kingdom*

Alternative Strategies: Focused Ultrasound and Other

Lesioning Techniques in Movement Disorders

José Obeso, *Spain*

CSPC Liaison: Andrea Kühn, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss and apply new DBS techniques such as segmented leads for current steering, imaging guided programming, VTA models
2. Discuss indications of DBS and explain motor and non-motor benefits and risks
3. Discuss the pros and cons of different surgical approaches in movement disorders

201: Plenary Session

Presidential Lectures

12:00 – 14:00 GMT

Chairs: Francisco Cardoso, *Brazil*

Claudia Trenkwalder, *Germany*

Stanley Fahn Lecture

Werner Poewe, *Austria*

C. David Marsden Lecture

Hiroshi Shibasaki, *Japan*

Junior Award Lectures

To Be Announced

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

Claudia Trenkwalder, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

MDS-ES Regional Assembly

14:00 – 14:30 GMT

All participants from Europe are encouraged to attend.

301: Parallel Session

COVID -19 and Movement Disorders

14:30 – 16:30 GMT

Chairs: Huifang Shang, *Peoples Republic of China*

Indu Subramanian, *USA*

Neurological Manifestations in patients with COVID-19

Elena Moro, *France*

COVID-19 in Patients with Parkinson's Disease or

Movement Disorders

Alfonso Fasano, *Canada*

Caring of Patients with Movement Disorders in the

COVID-19 Era

Esther Cubo, *Spain*

CSPC Liaison: Buz Jinnah, *USA*

Recommended Audience: Clinical Academicians, Practitioners Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Summarize the current knowledge about the neurological manifestations and neuropathology in subjects affected by the COVID-19
2. Summarize the clinical phenomenology and outcomes of the COVID-19 disease in patients with Parkinson's disease and other movement disorders
3. Discuss the impact of the COVID-19 pandemic on the clinical care of patients with movement disorders, and the available strategies to ensure continuity of care and best outcomes

SUNDAY, SEPTEMBER 13, 2020

302: Parallel Session

MSA and Pure Autonomic Failure

14:30 – 16:30 GMT

Chairs: Howard Hurtig, *USA*
Ryosuke Takahashi, *Japan*

Molecular Mechanisms
To Be Announced

The Challenge of Early Diagnosis
Wassilios Meissner, *France*

Pure / Isolated Autonomic Failure
Lucy Kaufmann, *USA*

CSPC Liaison: Pietro Cortelli, *Italy*
Ryosuke Takahashi, *Japan*

Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the role of alpha-synuclein in the initiation and progression of neurodegeneration across Parkinson's disease and atypical parkinsonism
2. Recognize Multiple System Atrophy at an early stage
3. Recognize Pure/Isolated Autonomic failure and discuss its role in predicting the onset of other synucleinopathies (MSA, DLB, PD)

303: Parallel Session

Update on Functional Movement Disorders

14:30 – 16:30 GMT

Chairs: Mark Edwards, *United Kingdom*
Mark Hallett, *USA*

Phenomenology
Francesca Morgante, *United Kingdom*

Electrophysiology and Imaging
Tereza Serranova, *Czech Republic*

Psychological Aspects to Aetiology and Management
Timothy Nicholson, *United Kingdom*

CSPC Liaison: Beomseok Jeon, *South Korea*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the phenomenology of functional movement disorders
2. Summarize the electrophysiological and imaging features of functional movement disorders
3. Discuss the psychopathology and management of functional movement disorders

304: Parallel Session

Update on Genetics of Movement Disorders

14:30 – 16:30 GMT

Chairs: Christine Klein, *Germany*
Carolyn Sue, *Australia*

Parkinsonism
Chin-Hsien Lin, *Taiwan*

Dystonia
Patricia Maria Carvalho Aguiar, *Brazil*

Ataxia
Martin Paucar Arce, *Sweden*

CSPC Liaison: Carolyn Sue, *Australia*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Summarize recently identified genes related to Parkinson's disease and parkinsonism
2. Summarize recently identified genes related to dystonia
3. Summarize recently identified genes related to ataxia

305: Parallel Session

Heterogeneity of Parkinson's Disease: Clinical Phenotypes and Progression

14:30 – 16:30 GMT

Chairs: Nabila Dahodwala, *USA*
Connie Marras, *Canada*

Influence of the Genetic Determinants
Clemens Scherzer, *USA*

Role of Environment, Lifestyle and Comorbidities
Connie Marras, *Canada*

Lessons from Large Cohort Studies
Rodolfo Savica, *USA*

CSPC Liaison: Claudia Trenkwalder, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the influence of different genetic variants (rare/Mendelian, intermediate-effects variants such as GBA and LRRK2-G2019S, and common GWAS variants) on phenotypes and progressions of Parkinson's disease
2. Discuss the influence of environment, diet, exercise, comorbidities and inflammation on the heterogeneity of Parkinson's disease
3. Discuss the potential of ongoing large longitudinal cohorts-studies to understand Parkinson's disease heterogeneity

SUNDAY, SEPTEMBER 13, 2020

306: Parallel Session

Huntington's Disease Continuum and Non-Huntington's Chorea

14:30 – 16:30 GMT

Chairs: Joaquim Ferreira, *Portugal*
Amanda Krause, *South Africa*

The Natural History of Huntington's Disease
G. Bernhard Landwehrmeyer, *Germany*

When Genetic Testing is Negative: Huntington's Phenocopies
Amanda Krause, *South Africa*

A Critical Appraisal of Clinical Trials in Huntington's Disease
Joaquim Ferreira, *Portugal*

CSPC Liaison: Francisco Cardoso, *Brazil*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the natural history of Huntington's Disease
2. List the differential diagnosis of Huntington's Disease phenocopies
3. Appraise recent clinical trials in Huntington's Disease

401: Teaching Course

Cognitive and Psychiatric Issues in the Parkinsonian Spectrum

14:30 – 16:30 GMT

Chairs: Cristian Falup-Pecurariu, *Romania*
James Morley, *USA*

Apathy: Why, Who, and What to Do About It
Marcelo Merello, *Argentina*

It's Not Just MCI / Dementia: The Many Cognitive Changes in Parkinsonism
Madeleine Sharp, *Canada*

Parkinson's Disease Treatments: How do They Change Neuropsychiatric Symptoms?
Daniel Weintraub, *USA*

CSPC Liaison: Ron Postuma, *Canada*

Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the pathophysiology, disease spectrum and management of apathy in parkinsonian conditions
2. Evaluate the broad spectrum of non-dementia cognitive changes in parkinsonian conditions
3. Differentiate treatment vs. disease-related effects on neuropsychiatric symptoms in Parkinson's disease

402: Teaching Course

Dystonia, Ataxia, and Tics

14:30 – 16:30 GMT

Chairs: Cynthia Comella, *USA*
Susanne Schneider, *Germany*

My Approach to Dystonia
Susanne Schneider, *Germany*

My Approach to Ataxia
José Luiz Pedrosa, *Brazil*

My Approach to Tic Disorders
Tamara Pringsheim, *Canada*

CSPC Liaison: Ron Postuma, *Canada*

Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the phenomenology and diagnostic approach to dystonia
2. Describe the phenomenology and diagnostics approach to ataxia
3. Summarize the phenomenology and diagnostic approach to tic disorders

MDS-Africa Regional Assembly

17:30 – 18:00 GMT

All participants from the African continent are encouraged to attend.

501: Skills Workshop

A Multidisciplinary Approach for Palliative Care

18:00 – 19:30 GMT

This session aims to help providers identify and manage palliative care needs, collaborate with other allied healthcare team members, and develop advance care planning with patients, families and their caregivers.

Stefan Lorenzl, *Germany*
Janis Miyasaki, *Canada*

CSPC Liaison: Claudia Trenkwalder, *Germany*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the relevance of palliative care in movement disorders
2. Develop a multidisciplinary approach to the management of patients in advanced care

SUNDAY, SEPTEMBER 13, 2020

502: Skills Workshop

DBS and Functional Communication in Parkinson Disease: Insights and Intervention 18:00 – 19:30 GMT

In this interactive session, the faculty will examine the impact of deep brain stimulation on speech intelligibility in Parkinson's disease. Evidence-based interventions will be compared to optimize functional communication.

Elina Tripoliti, *United Kingdom*
Michelle Troche, *USA*

CSPC Liaison: Terry Ellis, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Examine the impact of deep brain stimulation on speech intelligibility in Parkinson's disease
2. Compare treatment strategies to optimize functional communication in Parkinson's disease

503: Skills Workshop

Imaging in Movement Disorders 18:00 – 19:30 GMT

In this interactive session, the faculty will review the nuts and bolts of how radioisotope imaging, MRI, and ultrasonography are used for diagnosis and prognostication in movement disorders.

Marios Politis, *United Kingdom*
Klaus Seppi, *Austria*

CSPC Liaison: Per Borghammer, *Denmark*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe how PET and SPECT are used for the diagnosis, prognostication, and as progression markers of movement disorders
2. Describe the application of anatomical and functional MRI, and ultrasonography in the diagnosis, prognostication, and as progression markers of movement disorders

504: Skills Workshop

Phenomenology of Movement Disorders for Young Neurologists: Semiological Tricks and Pitfalls 18:00 – 19:30 GMT

In this interactive session, the faculty will discuss tricks and maneuvers they employ in clinical practice for the detection and examination of Movement Disorders.

Mona Obaid, *Saudi Arabia*
Mayela Rodriguez Violante, *Mexico*

CSPC Liaison: Oscar Gershanik, *Argentina*

Recommended Audience: Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Explore the phenomenology of Movement Disorders
2. Apply semiological tricks to better detect and examine Movement Disorders

601: Special Topics in Movement Disorders

Big Data Analytics in Clinical Research for Movement Disorders 18:00 – 19:30 GMT

In this session the Faculty will discuss the impact of big data analytics in the current clinical research on Parkinson's disease and other movement disorders, as well as the potential implications of the research findings in the clinical management.

Ivo Dinov, *USA*
Allison Willis, *USA*

CSPC Liaison: Roongroj Bhidayasiri, *Thailand*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the concept of big data analytics and the impact in clinical research in the field of movement disorders
2. Discuss findings from studies based on big data analytics, and their potential implications in the clinical management

602: Special Topics in Movement Disorders

Revisiting the Role of Non-Neuronal Cells in Parkinson's Disease 18:00 – 19:30 GMT

In this interactive session, the faculty will discuss recent data suggesting that brain non-neuronal cells, including glial and inflammatory cells, are involved in the pathogenesis and pathophysiology of Parkinson's disease.

To Be Announced
David Sulzer, *USA*

CSPC Liaison: Etienne Hirsch, *France*

Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the roles for non-neuronal cells in the pathophysiology of Parkinson's disease
2. Describe the putative roles for non-neuronal cells in the pathogenesis

701: Video Session

Gait Disorders 18:00 – 19:30 GMT

In this interactive session, participants will gain knowledge on different gait disorders through illustrative videos. Key features of gait disorders and different treatment strategies will be discussed, including surgical interventions.

Nir Giladi, *Israel*
Evzen Ruzicka, *Czech Republic*

CSPC Liaison: Andrea Kühn, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Review the clinical features of normal gait and recognize key abnormalities of gait disorders
2. Recognize specific dysfunction in gait disorders, discuss differential diagnosis and the respective therapeutic management

SUNDAY, SEPTEMBER 13, 2020

702: Video Session

Tardive Syndromes and Other Drug Induced Movement Disorders

18:00 – 19:30 GMT

In this interactive session, the faculty will demonstrate iatrogenic movement disorders in a case-based format, highlighting acute, chronic, and tardive syndromes, emphasizing phenotypic features that can be overlooked or misattributed to other disorders. Pearls and pitfalls of drug-related complications will be discussed.

Hubert Fernandez, *USA*

Deborah Hall, *US*

CSPC Liaison: Alberto Espay, *USA*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize typical and atypical forms of tardive syndromes and distinguish from mimics
2. Identify clinical clues associated with drug-induced movement disorders

MDS Video Challenge (non CME)

19:30 – 22:30 GMT

Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host world-renowned Movement Disorders experts in guiding participants through unique Movement Disorder cases. The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by Movement Disorder Experts. Awards will be given for the most interesting and challenging cases. Country pride will add an enjoyable spirit of competition to this event. The goal of this session is for participants to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

Featured Experts:

Bettina Balint, *United Kingdom*

Orlando Barsottini, *Brazil*

Kailash Bhatia, *United Kingdom*

Francisco Cardoso, *Brazil*

Roberto Erro, *Italy*

Alberto Espay, *USA*

Alfonso Fasano, *Canada*

Jennifer Friedman, *USA*

Victor Fung, *Australia*

Christos Ganos, *Germany*

Dan Healy, *Ireland*

Marina Koning-Tijssen, *Netherlands*

Manju Kurian, *United Kingdom*

Tim Lynch, *Ireland*

Werner Poewe, *Austria*

Stephen Reich, *USA*

Maria Stamelou, *Greece*

MONDAY, SEPTEMBER 14, 2020

MDS Video Challenge (Encore Presentation)

2:00 – 5:00 GMT

Please see page 15 for complete description.

202: Plenary Session

Treatable, Rare Movement Disorders Not to Miss

12:00 – 14:00 GMT

Chairs: Victor Fung, *Australia*
Mayela Rodriguez-Violante, *Mexico*

Clinical Approach
Jennifer Friedman, *USA*

Diagnostic Workup
Manju Kurian, *United Kingdom*

Current and Future Treatments
Buz Jinnah, *USA*

CSPC Liaison: Maria Stamelou, *Greece*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Appraise clinically a patient with a suspected treatable, rare movement disorder and recognize clinical clues not to be missed
2. Decide, determine and interpret the necessary investigations for a patient with a suspected treatable, rare movement disorder
3. Apply current therapies and identify upcoming new therapy options for rare movement disorders

203: Plenary Session

Parkinson's Disease Biomarkers: A Multidisciplinary Approach

12:00 – 14:00 GMT

Chairs: Per Borghammer, *Denmark*
Andrew Siderowf, *USA*

Update on Imaging Biomarkers for Parkinson's Disease
A. Jon Stoessl, *Canada*

Clinical Utility of Fluid Biomarkers for Parkinson's Disease
Brit Mollenhauer, *Germany*

Peripheral Pathology as a Parkinson's Disease Biomarker
Charles Adler, *USA*

CSPS Liaison: Andrew Siderowf, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Evaluate the clinical value of imaging biomarkers, including emerging PET and SPECT ligands and MRI
2. Describe current status of biochemical biomarkers for Parkinson's disease
3. Summarize recent developments in peripheral tissue assays for alpha-synuclein pathology in Parkinson's disease

307: Parallel Session

Innovative Models in the Integrated Management of Parkinson's Disease

14:30 – 16:30 GMT

Chairs: Bastiaan Bloem, *Netherlands*
Terry Ellis, *USA*

Interdisciplinary Team Models of Care in Parkinson's Disease
Jennifer Goldman, *USA*

An Integrated Telemedicine Approach in Parkinson's Disease
Mark Guttman, *Canada*

Integrated Palliative Care in Parkinson's Disease: Timing Matters
Maya Katz, *USA*

CSPC Liaison: Terry Ellis, *USA*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe interdisciplinary team models of care to optimize the management of Parkinson's disease
2. Discuss innovative models on integrated care using telehealth in Parkinson's disease
3. Describe a palliative care model integrated over the disease continuum in Parkinson's disease

308: Parallel Session

Sleep Disorders in Parkinsonism: Science and Clinical Aspects

14:30 – 16:30 GMT

Chairs: Roongroj Bhidayasiri, *Thailand*
Ron Postuma, *Canada*

Basic Science Aspects of RBD
To Be Announced

Clinical Aspects of RBD
Ambra Stefani, *Austria*

Sleep Disorders in Atypical Parkinsonism
Federica Provini, *Italy*

CSPC Liaison: Per Borghammer, *Denmark*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the pathophysiology and neuropathology underlying RBD
2. Describe clinical manifestations of RBD, their relationship with other clinical features, and management
3. Describe prominent sleep disorders in atypical parkinsonisms, their relation with other clinical features, and management

MONDAY, SEPTEMBER 14, 2020

309: Parallel Session

Update on Recent Clinical Trials

14:30 – 16:30 GMT

Chairs: Hubert Fernandez, *USA*
Oscar Gershanik, *Argentina*

Parkinson's Disease
Tatyana Simuni, *USA*

Atypical Parkinsonian Disorders
Günter Högl, *Germany*

Huntington's Disease
Blair Leavitt, *Canada*

CSPC Liaison: Wassilios Meissner, *France*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss recent clinical trials in Parkinson's disease
2. Review recent clinical trials for atypical parkinsonian disorders
3. Discuss recent clinical trials for hyperkinetic movement disorders

310: Parallel Session

The Crossroads of Spasticity and Ataxia

14:30 – 16:30 GMT

Chairs: Orlando Barsottini, *Brazil*
Brent Fogel, *USA*

Clinical Syndromes and Diagnostic Evaluation
To Be Announced

Biological Basis
Brent Fogel, *USA*

Management
Carlos Henrique Camargo, *Brazil*

CSPC Liaison: Buz Jinnah, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the clinical features and diagnostic workup of syndromes that feature spasticity and ataxia
2. Summarize the pathogenesis of spasticity and ataxia
3. Describe management strategies for clinical syndromes that combine spasticity and ataxia

311: Parallel Session

Advanced Multi-Modal Imaging and Big Imaging Data in Parkinson's Disease

14:30 – 16:30 GMT

Chairs: A. Jon Stoessl, *Canada*
Antonio Strafella, *Canada*

Multi-Modal Imaging of the Braak Stages and Parkinson's Disease Subtypes
Per Borghammer, *Denmark*

Multi-Modal Imaging for Diagnosis, Prognosis and Progression
Jee-Young Lee, *South Korea*

Simulating Parkinson's Disease in Computer Models and Using A.I. for Big Imaging Data
Alain Dagher, *Canada*

CSPC Liaison: Per Borghammer, *Denmark*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe how multi-modal imaging enables visualization of damage to distinct neurotransmitter systems in Parkinson's disease
2. Describe how multi-modal MRI and other imaging techniques are used for diagnosis, prognostication, and as progression markers
3. Describe computer simulations of Parkinson's disease and how artificial intelligence algorithms allow in-depth analysis of very large imaging datasets

403: Teaching Course



Atypical Parkinsonisms: Clinical Overview

14:30 – 16:30 GMT

Chairs: Carlo Colosimo, *Italy*
John Duda, *USA*

PSP/CBD
Marina Picillo, *Italy*

MSA
Han-Joon Kim, *South Korea*

Clinical Look-Alikes
Kailash Bhatia, *United Kingdom*

CSPC Liaison: Ron Postuma, *Canada*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Evaluate the clinical spectrum and imaging features of PSP/CBS
2. Evaluate the clinical spectrum and imaging features of MSA
3. Discuss the disorders which can clinically mimic PSP, CBD, and MSA

MONDAY, SEPTEMBER 14, 2020

404: Teaching Course

Update on Neurosurgery for Movement Disorders

14:30 – 16:30 GMT

Chairs: Elena Moro, *France*
Steve Tisch, *Australia*

DBS for Parkinson's Disease: Who, Where, and How?
Steve Tisch, *Australia*

DBS for Dystonia: Who, Where, and How?
Andrea Kühn, *Germany*

DBS and Lesioning in Tremor
Günther Deuschl, *Germany*

CSPC Liaison: Ron Postuma, *Canada*

Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Identify good candidates for DBS surgery in PD, the best surgical target, and novel types of segmented lead technology
2. Identify good candidates for DBS in dystonia, the outcome over the long term, and novel types of adaptive stimulation
3. Identify how to select candidates for surgery in tremor, how to use DBS, and when surgical vs. ultrasound lesioning should be used

901: Science of Industry (non-CME)

Antisense Oligonucleotides for Treating Movement Disorders

14:30 – 16:30 GMT

See page page 26 for complete session information.

505: Skills Workshop

Managing Comorbidities and Polypharmacy Issues in Parkinson's Disease

18:00 – 19:30 GMT

In this interactive session, the faculty will discuss common comorbidities and the polypharmacy these lead to in the management of Parkinson's disease.

David Burn, *United Kingdom*
Tove Henriksen, *Denmark*

CSPC Liaison: Tove Henriksen, *Denmark*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the most common comorbidities in Parkinson's disease
2. Manage the comorbidities and the related polypharmacy in Parkinson's disease

506: Skills Workshop

Botulinum Toxins: A Case-Based Approach

18:00 – 19:30 GMT

In this interactive session, the faculty will use a case-based approach to describe the use of botulinum toxins for the most common forms of dystonia and spasticity.

Carlo Colosimo, *Italy*
Andres Deik, *USA*

CSPC Liaison: Buz Jinnah, *USA*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe optimal strategies for the application of botulinum toxins for the more common forms of dystonia such as cervical dystonia, blepharospasm, and limb dystonia
2. Describe the optimal strategies for the application of botulinum toxins for the treatment of the more common forms of spasticity affecting the upper and lower limb

507: Skills Workshop

New Perspectives on Phenotype-Genotype Relationships

18:00 – 19:30 GMT

In this interactive session, faculty will describe various types of genotype-phenotype relationships, how to apply genetic testing for diagnosis in different movement disorders, and several online tools available for understanding the outcomes of genetic testing.

Pedro Gonzalez-Alegre, *USA*
Joanne Trinh, *Germany*

CSPC Liaison: Buz Jinnah, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the sometimes complex relationships between various genotypes and their associated phenotypes
2. Describe some of the tools available to help the clinician make better use of the results of genetic testing for diagnosis

MONDAY, SEPTEMBER 14, 2020

603: Special Topics in Movement Disorders

Physical Exercise and Parkinson's Disease

18:00 – 19:30 GMT

In this interactive session, the faculty will discuss the role of physical exercise in modifying the risk of developing Parkinson's disease and the disease progression.

Terry Ellis, *USA*
Priya Jagota, *Thailand*

CSPC Liaison: Beomseok Jeon, *South Korea*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the role of physical exercise in modifying the risk for developing Parkinson's disease
2. Discuss the role of exercise in modifying Parkinson's disease progression

604: Special Topics in Movement Disorders

Setting Up Your Telemedicine Clinic

18:00 – 19:30 GMT

In this interactive session, participants will gain practical knowledge on the resources needed to set up a telemedicine clinic. Faculty will also discuss both the advantages and disadvantages of this interface for delivery of care and highlight obstacles, potential pitfalls, and opportunities for future enhancements.

Piu Chan, *People's Republic of China*
Nijdeka Okubadejo, *Nigeria*
Meredith Spindler, *USA*

CSPC Liaison: Alberto Espay, *USA*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Apply readily available technology resources into an interface for telemedicine
2. Recognize the challenges and opportunities of a telemedicine clinic

605: Special Topics in Movement Disorders

How to Become a Successful Movement Disorders Specialist

18:00 – 19:30 GMT

In this interactive session, participants will gain insight on the best approaches to pursue a career in Movement Disorders.

Beomseok Jeon, *South Korea*
To Be Announced

CSPC Liaison: Oscar Gershanik, *Argentina*

Recommended Audience: Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Choose the right career path, and acquire the necessary skills to become a successful Movement Disorders Specialist
2. Recognize the importance of searching for good mentors when pursuing specialization

703: Video Session

Eye Movement Disorders

18:00 – 19:30 GMT

In this interactive session, attendees will learn bedside examination techniques, recognize categories of abnormal eye movements, and become familiar with ocular and oculomotor abnormalities in many movement disorders.

Tim Anderson, *New Zealand*
Joyce Liao, *USA*

CSPC Liaison: Shen Yang Lim, *Malaysia*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Undertake a bedside neuro-ophthalmological examination relevant to movement disorders
2. Describe characteristic clinical ocular and eye movement abnormalities that aid diagnosis in common and uncommon movement disorders

704: Video Session

Movement Disorder Emergencies

18:00 – 19:30 GMT

In this interactive session, the faculty will show videos of hypokinetic and hyperkinetic movement disorder emergencies, and discuss the practical management of these conditions

Steven Frucht, *USA*
Asha Kishore, *India*

CSPC Liaison: Roongroj Bhidayasiri, *Thailand*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize clinical settings and signs of hypokinetic and hyperkinetic movement disorder emergencies, including those related to device-aided therapies
2. Outline management strategies of various movement disorder emergencies

TUESDAY, SEPTEMBER 15, 2020

204: Plenary Session

Neuroscience Bridges

12:00 – 14:00 GMT

Chairs: Vincenzo Bonifati, *Netherlands*
Etienne Hirsch, *France*

Speakers: Karl Deisseroth, *USA*
Beth Stevens, *USA*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*
Etienne Hirsch, *France*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

312: Parallel Session



The Evolving Spectrum of Movement Disorder Tauopathies

14:30 – 16:30 GMT

Chairs: Adam Boxer, *USA*
Maria Stamelou, *Greece*

Clinical Spectrum
Maria Stamelou, *Greece*

Biomarkers
James Rowe, *United Kingdom*

Therapeutic Pipeline
Adam Boxer, *USA*

CSPC Liaison:
Wassilios Meissner, *France*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the spectrum of movement disorder tauopathies
2. Discuss biomarkers for movement disorder tauopathies
3. Describe the therapeutics pipeline for movement disorder tauopathies

313: Parallel Session

Essential Tremor, Dystonia and Their Relationships

14:30 – 16:30 GMT

Chairs: Kailash Bhatia, *United Kingdom*
Louis Tan, *Singapore*

The Phenotypic Spectrum of Essential Tremor-Plus
Syndromes

Franziska Hopfner, *Germany*

The Phenotypic Spectrum of Tremor in Dystonias
Aasef Shaikh, *USA*

Differentiating Essential Tremor-Plus and Dystonic
Tremor: Neurophysiological Tools
Maja Kojovic, *Slovenia*

CSPC Liaison: Marisa Stamelou, *Greece*

Recommended Audience: Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe and recognize the phenotypic spectrum of essential tremor-plus syndromes
2. Examine and identify the characteristics of tremor in a patient with dystonia
3. Evaluate neurophysiological tools for the differential diagnosis of essential tremor and dystonia syndromes

314: Parallel Session

Microbiome and the Gut-Brain Axis

14:30 – 16:30 GMT

Chairs: Carolyn Sue, *Australia*
Ruey-Meei Wu, *Taiwan*

The Gut Microbiome in Health and Disease
To Be Announced

The Gut Microbiome in the Pathogenesis of Parkinson's
Disease

Heinz Reichmann, *Germany*

Perspectives for Clinical Management
Ai Huey Tan, *Malaysia*

CSPC Liaison: Carolyn Sue, *Australia*

Recommended Audience: Basic Scientists, Clinical Academicians, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Summarize the scientific evidence for the role of the gut microbiome in health and disease
2. Appraise animal studies investigating the role of the gut microbiome in the pathogenesis of Parkinson's disease
3. Appraise clinical studies investigating the role of the gut microbiome in the pathogenesis of Parkinson's disease

TUESDAY, SEPTEMBER 15, 2020

315: Parallel Session

DNA Repeat Expansions: Old and New Forms

14:30 – 16:30 GMT

Chairs: To Be Announced
Henry Paulson, *USA*

Genotypes and Phenotypes
To Be Announced

Molecular Mechanisms
Henry Paulson, *USA*

Emerging Therapeutic Avenues
Edward Wild, *United Kingdom*

CSPC Liaison: Jennifer Friedman, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the genetic and clinical spectrum of repeat expansions in movement disorders
2. Describe the molecular mechanisms of repeat expansion disorders
3. Describe the emerging therapeutic avenues for repeat expansion disorders

316: Parallel Session

Dementia with Lewy Bodies (DLB)

14:30 – 16:30 GMT

Chairs: To Be Announced
Karen Marder, *USA*

Genetics Insights to the Pathogenesis
Rita Guerreiro, *United Kingdom*

Imaging
Kejal Kantarci, *USA*

Diagnosis and Management
To Be Announced

CSPC Liaison: Karen Marder, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the role of genetic variants in the pathogenesis of Lewy Body disorders
2. Discuss the role of imaging in differential diagnosis of Lewy Body disorders
3. Identify multidisciplinary approaches to Lewy Body disorders

317: Parallel Session

Gene-driven Therapies Under Development for Parkinson's Disease

14:30 – 16:30 GMT

Chairs: Etienne Hirsch, *France*
Dan Kremens, *USA*

At the Crossroads Between Gaucher's and Parkinson's Disease
Ellen Sidransky, *USA*

LRRK2 Inhibition as a Target for Intervention in Parkinson's Disease
Elisa Greggio, *USA*

Alpha-synuclein Aggregation as a Target for Therapeutic Intervention
Daniel Otzen, *Denmark*

CSPC Liaison: Tiago Outeiro, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the role of GBA1 as a genetic risk factor and target for intervention in Parkinson's disease
2. Discuss the current status of LRRK2 inhibition as a therapeutic strategy for Parkinson's disease
3. Compare different possible therapeutic strategies targeting alpha-synuclein aggregation

405: Teaching Course



Parkinson's Disease Biomarkers

14:30 – 16:30 GMT

Chairs: Shengdi Chen, *People's Republic of China*
Brit Mollenhauer, *Germany*

What Makes a Good Biomarker?
Michele Hu, *United Kingdom*

Key Updates in Fluid and Tissue Biomarkers of Parkinson's Disease
Alice Chen-Plotkin, *USA*

Key Updates in Imaging Biomarkers
Kathleen Poston, *USA*

CSPC Liaison: Ron Postuma, *Canada*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss different types and uses of biomarkers in Parkinson's disease
2. Summarize key updates in the field of Parkinson's disease fluid and tissue biomarkers
3. Summarize updates in the field of Parkinson's disease neuroimaging biomarkers

TUESDAY, SEPTEMBER 15, 2020

406: Teaching Course

Autonomic Disturbances in Movement Disorders

14:30 – 16:30 GMT

Chairs: Pietro Cortelli, *Italy*
David Goldstein, *USA*

Physiology and Pathophysiology
David Goldstein, *USA*

Clinical Evaluation and Diagnostic Tests
Valeria Iodice, *United Kingdom*

Management
Pietro Cortelli, *Italy*

CSPC Liaison: Ron Postuma, *Canada*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Recognize the important movement disorders associated with autonomic dysfunction
2. Discuss clinical testing for autonomic dysfunction in movement disorders
3. Evaluate pathophysiology and treatment options for autonomic dysfunction in movement disorders

902: Science of Industry (non-CME)

Immunotherapy for Proteinopathies

14:30 – 16:30 GMT

See page page 26 for complete session information.

508: Skills Workshop

Genetic Testing, Counseling and Ethical Issues

18:00 – 19:30 GMT

In this interactive session, the faculty will discuss basic issues regarding genetic testing and counseling for movement disorders, including the rationale, process, challenges and ethical concerns, such as privacy and testing minors, that may arise. Faculty will provide insights regarding ethical aspects of genetics in movement disorders in the next generation sequencing era. Case examples will be used to illustrate the pros and cons of genetic testing, ethical considerations, and challenges faced by clinicians, geneticists, and patients and their families.

Roy Alcalay, *USA*
Christine Klein, *Germany*
Avi Orr-Urtreger, *Israel*

CSPC Liaisons: Jennifer Goldman, *USA*
Karen Marder, *USA*

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss genetic testing and counseling for movement disorders, including the “when, what, why, and how”
2. Recognize the ethical issues relevant to genetic testing and the management of patients with movement disorders

509: Skills Workshop

How to Use the MDS-UPDRS

18:00 – 19:30 GMT

In this interactive session, movement disorders experts will facilitate the understanding of participants on the core elements of the MDS-UPDRS and enable them to become fluent in the grading system. Participants will have an opportunity to practice on test cases and determine how to use this standardized measure to optimize clinical and research evaluations, train others in a standardized assessment of Parkinson's disease, and increase communication amongst providers.

Emilia Gatto, *Argentina*
Matej Skorvanek, *Slovakia*

CSPC Liaison: Veronica Santini, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Evaluate patients and participants in clinical and research settings with the MDS-UPDRS
2. Practice using the MDS-UPDRS through interactive exercises and test cases

510: Skills Workshop

Lessons From My Patients

18:00 – 19:30 GMT

Session Description: In this interactive session, experienced clinical specialists will discuss important lessons they have learned from patients, analyzing the important clinical features of the history and examination that aided in the diagnosis, as well as pitfalls of the evaluation process. Faculty will also discuss approaches to management and key features that assist in determining appropriate strategies.

Cynthia Comella, *USA*
Marie Vidailhet, *France*

CSPC Liaisons: Tove Henriksen, *Denmark*
Veronica Santini, *USA*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Interpret and critique the pertinent historical and examination elements that may be advantageous when diagnosis and management are elusive
2. Identify common pitfalls in the evaluation of movement disorders

TUESDAY, SEPTEMBER 15, 2020

606: Special Topics in Movement Disorders



Autonomic Dysfunction: Pathophysiology and Advanced Testing

18:00 – 19:30 GMT

In this interactive session, the pathophysiology and advanced methods for investigating, diagnosing and imaging cardiovascular, gastrointestinal and urogenital systems in Parkinson's disease and atypical parkinsonism will be illustrated. Participants will be able to discuss the relevance of advanced diagnostic techniques to define and manage neurogenic orthostatic hypotension, gastrointestinal and urogenital dysfunctions.

Ryuji Sakakibara, Japan
Paola Sandroni, USA

CSPC Liaison: Pietro Cortelli, Italy

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Assess the pathophysiology of neurogenic orthostatic hypotension, gastrointestinal and urogenital autonomic dysfunctions
2. Interpret the results of advanced investigations for planning appropriate management of these autonomic dysfunctions

607: Special Topics in Movement Disorders

IPCs and Organoids for Parkinson's Disease

18:00 – 19:30 GMT

In this session, the technology of induced pluripotent stem cells (iPS) and brain organoids as innovative tools for Parkinson's disease modeling and development of novel therapies will be discussed.

Wado Akamatsu, Japan
Eng-King Tan, Singapore

CSPC Liaison: Ryosuke Takahashi, Japan

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Illustrate the application of human pluripotent stem cell technology and brain organoids to study the molecular mechanisms of Parkinson's disease
2. Discuss the potential of human pluripotent stem cell and organoid technologies for the development of novel therapies for Parkinson's disease

608: Special Topics in Movement Disorders

Metals and Calcium in my Brain

18:00 – 19:30 GMT

In this interactive session the presenters will discuss clinical and imaging aspects of movement disorders related to iron, copper, manganese, and calcium brain accumulation. The audience will learn important tips to clinically distinguish different forms of these disorders and the available treatment options.

Annu Aggarwal, India
Miryam Carecchio, Italy

CSPC Liaison: Orlando Barsottini, Brazil

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the phenotypic spectrum of movement disorders associated with brain metal accumulations
2. Recognize different imaging hallmarks of these disorders

609: Special Topics in Movement Disorders

Nutrition and Microbiome in Health and Neurodegenerative Disease

18:00 – 19:30 GMT

In this interactive session, faculty will discuss nutrition and the microbiome in health and disease. They will present research on nutrition and dietary patterns and their effects on maintaining health and the development of disease, cognitive decline, and parkinsonism. Faculty will discuss the microbiome and how it relates to the pathogenesis of Parkinson's disease, different fecal and blood microbiota in animal and human models, and implications for research and clinical care.

John Duda, USA
Qin Xiao, People's Republic of China

CSPC Liaison: Jennifer Goldman, USA

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe how nutrition and different dietary patterns influence both health and disease
2. Discuss the role of the microbiome in the pathogenesis of Parkinson's disease, highlighting evidence from animal models to human studies

705: Video Session

Pediatric Hyperkinetic Movement Disorders: Approach to a Child who Moves Too Much

18:00 – 19:30 GMT

In this interactive session, the presenters will demonstrate with illustrative videos the wide phenotypic spectrum of hyperkinetic pediatric movement disorders. The audience will also observe video cases of potentially treatable hyperkinetic pediatric movement disorders that are important not to miss.

Serena Galosi, Italy
Toni Pearson, USA

CSPC Liaisons: Orlando Barsottini, Brazil
Jennifer Friedman, USA

Recommended Audience: Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Describe the phenotypic spectrum of hyperkinetic movement disorders in children
2. Recognize potentially treatable hyperkinetic pediatric movement disorders

WEDNESDAY, SEPTEMBER 16, 2020

205: Plenary Session

Digital Health Technologies in Movement Disorders

12:00 – 14:00 GMT

Chairs: Roongroj Bhidayasiri, *Thailand*
Christopher Goetz, *USA*

Digital Health Technologies: The Toolbox in 2020
Walter Maetzel, *Germany*

Digital Technologies for Diagnosis and Disease Monitoring
Bastiaan Bloem, *Netherlands*

Digital Health Pathway for Personalized and Integrated Care
Alberto Espay, *USA*

CSPC Liaison: Roongroj Bhidayasiri, *Thailand*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Summarize the digital health technologies available for research and clinical care of movement disorders
2. Discuss opportunities and challenges of digital health technologies for diagnosis and disease monitoring in clinical trials and patients management
3. Discuss the concept of digital health pathway for patient-centered integrated care

206: Plenary Session

Translational Insights into New Parkinson's Disease-Modifying Therapies

12:00 – 14:00 GMT

Chairs: Joseph Jankovic, *USA*
Tiago Outeiro, *Germany*

Lysosomal Dysfunction in Parkinson's Disease: From Genetics to the Bedside
Leonidas Stefanis, *Greece*

The Immune System as a Target for Intervention in Parkinson's Disease
Malu Tansey, *USA*

Antibody-Based Therapies: Present and Future
Eliezer Masliah, *USA*

CSPC Liaison: Tiago Outeiro, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Discuss the potential of lysosome-targeted therapies in Parkinson's disease
2. Discuss the role of the immune system as a target for intervention in Parkinson's disease
3. Summarize the status of antibody-based therapies for Parkinson's disease

207: Plenary Session

Controversies in Movement Disorders

14:30 – 15:30 GMT

Chairs: Tove Henriksen, *Denmark*
Irene Litvan, *USA*

Antibodies Panels are Under-Utilized in Movement Disorders Diagnosis (YES)
Bettina Balint, *United Kingdom*

Antibodies Panels are Under-Utilized in Movement Disorders Diagnosis (NO)
Francisco Cardoso, *Brazil*

Clinical Judgement vs. A.I. Algorithms: A.I. Will Outperform the Clinical Neurologist in the Near Future (YES)

Roongroj Bhidayasiri, *Thailand*

Clinical Judgement vs. A.I. Algorithms: A.I. Will Outperform the Clinical Neurologist in the Near Future (NO)

Christopher Goetz, *USA*

CSPC Liaison: Vincenzo Bonifati, *Netherlands*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Debate the advantages and disadvantages of antibodies panels in movement disorders diagnosis
2. Debate whether artificial intelligence will outperform clinical judgement in the near future



WEDNESDAY, SEPTEMBER 16, 2020

208: Plenary Session

Highlights from 2020: Looking Toward 2021

15:30 – 16:30 GMT

Chairs:

Vincenzo Bonifati, *Netherlands*

Claudia Trenkwalder, *Germany*

Basic Science: Parkinson's Disease

Ryosuke Takahashi, *Japan*

Basic Science: Other Movement Disorders

Carolyn Sue, *Australia*

Clinical Studies: Parkinson's Disease

Shen Yang Lim, *Malaysia*

Clinical Studies: Other Movement Disorders

Orlando Barsottini, *Brazil*

CSPC Liaisons:

Vincenzo Bonifati, *Netherlands*

Claudia Trenkwalder, *Germany*

Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Non-Physician Health Professionals, Students/Residents/Trainees

At the conclusion of this session, participants should be better able to:

1. Critically review high-impact scientific discoveries in the field of movement disorders published in the past year, and important areas of scientific focus for 2021 research
2. Critically review high-impact clinical studies in the field of movement disorders published in the past year, and important ongoing trials with anticipated completion in 2020

MDS-PAS Regional Assembly

22:30 – 23:00 GMT

All participants from Pan America are encouraged to attend.

NON-CME EDUCATIONAL ACTIVITIES

SCIENCE OF INDUSTRY SESSION (NON-CME):

These interactive sessions will provide participants with a non-CME educational opportunity to learn about novel therapeutic agents under development by industry. Sessions may incorporate basic scientists or clinicians working in industry, and topics may address the biological rationale or development process for specific therapeutics in development within the field of Movement Disorders.

MONDAY, SEPTEMBER 14, 2020

901	Science of Industry (non-CME)
	Antisense Oligonucleotides for Treating Movement Disorders
	14:30 - 16:30 GMT
Chairs:	Stanley Fahn, <i>USA</i> Buz Jinnah, <i>USA</i>
	Biological Basis Stefan Pulst, <i>USA</i>
	Preclinical Treatment Pipeline To Be Announced
	Current Status of Clinical Development Lauren Boak, <i>Switzerland</i>
CSPC Liaison:	Wassilios Meissner, <i>France</i> Tiago Outeiro, <i>Germany</i>
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:	
1. Discuss the biological basis for using antisense oligonucleotides as treatment for movement disorders	
2. Summarize the results of preclinical studies using antisense oligonucleotides for treating movement disorders	
3. Discuss the current status of clinical trials using antisense oligonucleotides for treating movement disorders	

TUESDAY, SEPTEMBER 15, 2020

902	Science of Industry (non-CME)
	Immunotherapy for Proteinopathies
	14:30 - 16:30 GMT
Chairs:	Wassilios Meissner, <i>France</i> Tiago Outeiro, <i>Germany</i>
	Biological Basis Andrew Siderowf, <i>USA</i>
	Update on Preclinical Studies Warren Hirst, <i>USA</i>
	Current Status of Clinical Development Wagner Zago, <i>USA</i>
CSPC Liaisons:	Wassilios Meissner, <i>France</i> Tiago Outeiro, <i>Germany</i>
Recommended Audience: Basic Scientists, Clinical Academicians, Practitioners, Students/Residents/Trainees	
At the conclusion of this session, participants should be better able to:	
1. Discuss the biological basis for immunotherapy in neurological disease	
2. Summarize the results of preclinical studies based on immunotherapy strategies for treating movement disorders	
3. Summarize the current status of clinical trials based on immunotherapy strategies for treating movement disorders	

SPONSORED SYMPOSIA

Join daily at 16:30 GMT for our Sponsored Symposia. These industry-based informational sessions provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

SATURDAY, SEPTEMBER 12

AbbVie
ACADIA Pharmaceuticals, Inc.
Sunovion Pharmaceuticals, Inc.
Zambon

SUNDAY, SEPTEMBER 13

Acorda Therapeutics
Bial
Genentech, a Member of the Roche Group
Medtronic

MONDAY, SEPTEMBER 14

Neurocrine Biosciences, Inc.
Sanofi Genzyme

TUESDAY, SEPTEMBER 15

Teva

FACULTY LISTING

Charles Adler, USA
203

Annu Aggarwal, India
608

Wado Akamatsu, Japan
607

Roy Alcalay, USA
508

Tim Anderson, New Zealand
703

Angelo Antonini, Italy
102

Bettina Balint, Germany
207

Orlando Barsottini, Brazil
208, 310

Kailash Bhatia, United Kingdom
313, 403

Roongroj Bhidayasiri, Thailand
205, 207, 308

Bastiaan Bloem, Netherlands
205, 307

Lauren Boak, Switzerland
901

Vincenzo Bonifati, Netherlands
204, 208

Per Borghammer, Denmark
203, 311

Adam Boxer, USA
312

David Burn, United Kingdom
505

Carlos Henrique Camargo, Brazil
310

Francisco Cardoso, Brazil
103, 201, 207

Miryam Carecchio, Italy
608

Patricia Maria Carvalho Aguiar, Brazil
304

Piu Chan, Peoples Republic of China
604

Shengdi Chen, Peoples Republic of China
101, 405

Alice Chen-Plotkin, USA
405

Carlo Colosimo, Italy
403, 506

Cynthia Comella, USA
402, 510

Pietro Cortelli, Italy
406

Esther Cubo Delgado, Spain
301

Alain Dagher, Canada
311

Nabila Dahodwala, USA
305

Andres Deik, USA
506

Karl Deisseroth, USA
204

Günther Deuschl, Germany
104, 404

Ivo Dinov, USA
601

John Duda, USA
403, 609

Mark Edwards, United Kingdom
303

Terry Ellis, USA
307, 603

Alberto Espay, USA
205

Stanley Fahn, USA
901

Cristian Falup-Pecurariu, Romania
401

Alfonso Fasano, Canada
301

Hubert Fernandez, USA
309, 702

Joaquim Ferreira, Portugal
306

Brent Fogel, USA
310

Jennifer Friedman, USA
202

Steven Frucht, USA
704

Victor Fung, Australia
202

Serena Galosi, Italy
705

Emilia Gatto, Argentina
509

Oscar Gershanik, Argentina
101, 309

Nir Giladi, Israel
701

Christopher Goetz, USA
205, 207

Jennifer Goldman, USA
307

David Goldstein, USA
406

Pedro Gonzalez-Alegre, USA
507

Elisa Greggio, USA
317

Rita Guerreiro, United Kingdom
316

Mark Guttman, Canada
307

Deborah Hall, USA
702

Mark Hallett, USA
303

Tove Henriksen, Denmark
207, 505

Etienne Hirsch, France
204, 317

Warren Hirst, USA
902

Günter Höglinger, Germany
309

Franziska Hopfner, Germany
313

Michele Hu, United Kingdom
405

Howard Hurtig, USA
302

Valeria Iodice, United Kingdom
406

Priya Jagota, Thailand
603

Joseph Jankovic, USA
206

FACULTY LISTING

Beomseok Jeon, *South Korea*
101, 605

Hyder Jinnah, *USA*
202, 901

Kejal Kantarci, *USA*
316

Maya Katz, *USA*
307

Regina Katzenschlager, *Austria*
101

Horacio Kaufmann, *USA*
102

Lucy Kaufmann, *USA*
302

Han-Joon Kim, *South Korea*
403

Asha Kishore, *India*
704

Christine Klein, *Germany*
304, 508

Maja Kojovic, *Slovenia*
313

Amanda Krause, *South Africa*
306

Daniel Kremens, *USA*
317

Andrea Kuehn, *Germany*
104, 404

Manju Kurian, *United Kingdom*
202

G. Bernhard Landwehrmeyer, *Germany*
306

Blair Leavitt, *Canada*
309

Jee-Young Lee, *South Korea*
311

Y. Joyce Liao, *USA*
703

Shen-Yang Lim, *Malaysia*
208

Patricia Limousin, *United Kingdom*
104

Chin-Hsien Lin, *Taiwan*
304

Carol Lippa, *USA*
316

Irene Litvan, *USA*
207

Stefan Lorenzl, *Germany*
501

Pierre-Hervé Luppi, *France*
308

Walter Maetzler, *Germany*
205

Karen Marder, *USA*
316

Connie Marras, *Canada*
305

Eliezer Masliah, *USA*
206

Wassilios Meissner, *France*
302, 902

Marcelo Merello, *Argentina*
401

Janis Miyasaki, *Canada*
501

Brit Mollenhauer, *Germany*
203, 405

Francesca Morgante, *United Kingdom*
303

James Morley, *USA*
401

Elena Moro, *France*
301, 404

Timothy Nicholson, *United Kingdom*
303

Alice Nieuwboer, *Belgium*
101

Mona Obaid, *Saudi Arabia*
504

Jose Obeso, *Spain*
104

Njideka Okubadejo, *Nigeria*
604

Avi Orr-Urtreger, *Israel*
508

Daniel Otzen, *Denmark*
317

Tiago Outeiro, *Germany*
206, 902

Martin Paucar Arce, *Sweden*
304

Henry Paulson, *USA*
315

Toni Pearson, *USA*
705

José Luiz Pedrosa, *Brazil*
402

Marina Picillo, *Italy*
403

Werner Poewe, *Austria*
201

Marios Politis, *United Kingdom*
503

Kathleen Poston, *USA*
405

Ron Postuma, *Canada*
102, 308

Tamara Pringsheim, *Canada*
402

Federica Provini, *Italy*
308

Stefan Pulst, *USA*
901

Heinz Reichmann, *Germany*
314

Mayela Rodriguez Violante, *Mexico*
202, 504

James Rowe, *United Kingdom*
312

Evzen Ruzicka, *Czech Republic*
701

Ryuji Sakakibara, *Japan*
606

Paola Sandroni, *USA*
606

Rachel Saunders-Pullman, *USA*
103

Rodolfo Savica, *USA*
305

Clemens Scherzer, *USA*
305

Susanne Schneider, *Germany*
402

Anette Schrag, *United Kingdom*
102

Klaus Seppi, *Austria*
503

FACULTY LISTING

Tereza Serranova, *Czech Republic*
303

Aasef Shaikh, *USA*
313

Huifang Shang, *Peoples Republic of China*
301

Madeleine Sharp, *Canada*
401

Hiroshi Shibasaki, *Japan*
201

Andrew Siderowf, *USA*
203, 902

Ellen Sidransky, *USA*
317

Tatyana Simuni, *USA*
309

Matej Skorvanek, *Slovakia*
509

Meredith Spindler, *USA*
604

Maria Stamelou, *Greece*
312

Ambra Stefani, *Austria*
308

Leonidas Stefanis, *Greece*
206

Matthew Stern, *USA*
101

Beth Stevens, *USA*
204

A. Jon Stoessl, *Canada*
203, 311

Antonio Strafella, *Canada*
311

Indu Subramanian, *USA*
301

Carolyn Sue, *Australia*
208, 304, 314

David Sulzer, *USA*
602

Pille Taba, *Estonia*
101

Ryosuke Takahashi, *Japan*
208, 302

Ai Huey Tan, *Malaysia*
314

Louis Tan, *Singapore*
102, 313

Eng-King Tan, *Singapore*
607

Malu Tansey, *USA*
206

Stephen Tisch, *Australia*
404

Eduardo Tolosa, *Spain*
103

Claudia Trenkwalder, *Germany*
201, 208

Joanne Trinh, *Germany*
507

Elina Tripoliti, *United Kingdom*
502

Michelle Troche, *USA*
502

Yoshikazu Ugawa, *Japan*
103

Marie Vidailhet, *France*
510

Jens Volkmann, *Germany*
104

Ruth Walker, *USA*
103

Daniel Weintraub, *USA*
102, 401

Edward Wild, *United Kingdom*
315

Allison Willis, *USA*
601

Ruey-Meei Wu, *Taiwan*
314

Qin Xiao, *People's Republic of China*
609

Wagner Zago, *USA*
902

ACKNOWLEDGEMENTS

The International Congress of Parkinson's Disease and Movement Disorders Virtual Congress wishes to acknowledge the following commercial supporters:

DIAMOND LEVEL

abbvie

Bial

Keeping life
in mind.

Genentech
A Member of the Roche Group

Medtronic



 sunovion

PLATINUM LEVEL



ACORDA[®]
THERAPEUTICS

Medtronic

Sanofi Genzyme

teva

Fambon
1906

SILVER LEVEL



The MDS Virtual Congress also acknowledges the following sponsors who made their commitments by July 1: Abbott, Adamas Pharmaceuticals, Inc., Boston Scientific, Britannia Pharmaceuticals, ConvaTec, Defeat MSA Alliance, EVER Neuro Pharma GmbH, GE Healthcare Ltd, IPSEN, Kyowa Kirin, Merz Therapeutics, NeuroDerm, PD Neurotechnology, Ltd., Synergic Medical Technologies, Voyager Therapeutics

ACKNOWLEDGEMENTS

MARQUEE SPONSORS

abbvie



ACORDA®
THERAPEUTICS



Genentech
A Member of the Roche Group



Medtronic



uniQure



Advance.
Improve.
Educate.
Collaborate.



International Parkinson and
Movement Disorder Society

Become a Member of MDS

Join over 9,000 movement disorders professionals across the globe in working to disseminate knowledge and promote research to advance the field.

MDS Members receive the following benefits:

Peer Reviewed Journals: *Movement Disorders* and *Movement Disorders Clinical Practice*

Quarterly Newsletter: *Moving Along*

Reduced Course Registration Fees

Online Resources: CME activities; streaming content; and a video library with over 2,000 searchable videos

NON-MEMBER OPPORTUNITIES

Free One-Year Trial Membership
Open to Eligible Virtual Congress Participants

ASSOCIATE MEMBERSHIP

Non-members attending the Virtual Congress have the opportunity to receive membership with MOS absolutely free for a year. Eligible participants will be invited by e-mail to apply for free Associate Membership. Interested individuals are encouraged to apply online within 30 days of contact.

Learn more at www.movementdisorders.org/associate-membership.htm or contact the International Secretariat: MDS International Secretariat; 555 East Wells Street, Suite 1100; Milwaukee, WI 53202 USA; Tel: + 1 414-276-2145; Fax: + 1 414-276-3349; E-mail: membership@movementdisorders.org



www.movementdisorders.org/membership

Inbrija[®]

(levodopa inhalation powder)

FOR MORE INFORMATION, VISIT

INBRIJAinfo.com



ACORDA[®]
T H E R A P E U T I C S

ACORDA THERAPEUTICS, the stylized ACORDA THERAPEUTICS logo, INBRIJA and the INBRIJA logo are trademarks of Acorda Therapeutics, Inc. ©2020 Acorda Therapeutics, Inc. All rights reserved.

03/2020 INB8808

At Adamas our purpose
is to make everyday life
significantly better for people
affected by neurological diseases



For more information,
please visit our website at
www.adamaspharma.com

Bial

Keeping
life in
mind.



We have existed since 1924
to give you more and better health.
Caring for your life,
is more than a mission, it's our **dream**.
This dream remains as alive today as in the beginning.
And we know that the only way to realize it, is by innovating.
Innovation is the energy that feeds the dream.
That drives us to **search for new medicines**.
And keeps us working around the world.
Always **caring for your health**.

www.bial.com

VERCISE™

Deep Brain Stimulation Systems

SIMPLY ADVANCED



Simple and intuitive controls provide DBS programmers flexibility and options to manage patients' therapy.*

*One touch buttons make directional programming intuitive and simple.

Indications for Use: The Vercise™ Deep Brain Stimulation (DBS) Systems are indicated for use in bilateral stimulation of the subthalamic nucleus (STN) as adjunctive therapies in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson's disease (PD) that are not adequately controlled with medication.

Contraindications, warnings, precautions, side effects: Vercise DBS Systems, or any of their components, are contraindicated for: Diathermy as either a treatment for a medical condition or as part of a surgical procedure, Electroconvulsive Therapy (ECT) and Transcranial Magnetic Stimulation (TMS) as the safety of these therapies in patients implanted with Vercise DBS Systems has not been established, Magnetic Resonance Imaging (MRI), patients who are unable to operate the system, patients who are poor surgical candidates or who experience unsuccessful test stimulation. Refer to the Instructions for Use provided with Vercise DBS Systems or BostonScientific.com for potential adverse effects, warnings, and precautions prior to using this product.

Caution: U.S. federal law restricts this device to sale by or on the order of a physician. All trademarks are the property of their respective owners.

NM-557903-AA Copyright ©2018 by Boston Scientific Corporation or its affiliates. All rights reserved.

KYNMOBI™


(apomorphine HCl) sublingual film

NOW APPROVED

Sunovion Pharmaceuticals Inc. is a proud sponsor of the 2020 MDS Virtual Congress. To learn more about KYNMOBI and to register for product updates, please visit www.KYNMOBI.com.

For support services, call Sunovion Answers at 1-844-596-6624.



KYNMOBI and KYNMOBI™ are trademarks of Sunovion Pharmaceuticals Inc.
SUNOVION and  are registered trademarks of Sumitomo Dainippon Pharma Co., Ltd.
Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Sumitomo Dainippon Pharma Co., Ltd.
©2020 Sunovion Pharmaceuticals Inc. All rights reserved. 6/20 KYN-US-00002-20




INSIGHTEC

Transforming Patient Lives through
INCISIONLESS SURGERY

MR-guided Focused Ultrasound Treatment for
Essential Tremor & Tremor-Dominant Parkinson's Disease¹


¹<https://www.insightec.com/media/31393/exablate-neuroinfo-for-prescribers-usa.pdf>

www.insightec.com



Developing **non-invasive neuromodulation** for Parkinson's Disease

Our research is advancing our understanding of how Parkinson's disease alters brain activity and, consequently, how our **non-invasive neuromodulation** techniques may restore specific brain functions and relieve Parkinson's disease symptoms.

 **Synergic**
medical technologies, inc.
synergicmed.com



International Parkinson and
Movement Disorder Society

International Parkinson and Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA

